FM-CEMBE-Conferências
URI permanente para esta coleção:
Navegar
Entradas recentes
- Atherosclerosis : real-world insights from a Portuguese primary care databasePublication . Ascenção, Raquel; Alarcão, Joana; Fiorentino, Francesca; Gouveia, Miguel; Costa, João; Araújo, F.; Mello e Silva, A.; Borges, MargaridaObjectives: Cardiovascular disease remains the leading cause of death in Portugal and across the world. Atherosclerosis is the most common pathophysiologic process underlying CVD. Its clinical manifestations include coronary artery disease (CAD), cerebrovascular disease (CVD) and peripheral artery disease (PAD). This study aims to determine the clinical and demographic characteristics of adult patients with atherosclerosis in a Portuguese primary care comprehensive administrative database.
- PO104 placebo and nocebo responses in RLS : a meta-analysisPublication . Rodrigues, Filipe Brogueira; Duarte, Gonçalo Silva; Silva, Maria A.; Fernandes, Ricardo M.; Abreu, Daisy; Mestre, Tiago; Costa, João; Trenkwalder, Claudia; Ferreira, Joaquim JObjective: Our goals were to estimate the placebo and nocebo responses in restless legs syndrome (RLS). Methods: Databases were searched up to October 2015. Randomised, double-blind, placebo-controlled trials of RLS patient were included. ‘Placebo response’ was defined as the within-group change from baseline, using any scale measuring RLS severity or disability. ‘Nocebo response’ was defined as the proportion of patients experiencing adverse events in the placebo arm. Random-effects meta-analysis was used to pool data. Results: We included 5046 participants. Pooled placebo response effect size was −1.41 (95%CI:−1.56-−1.25), corresponding to −6.58 points in the International RLS Study Group Scale (IRLS). Pooled nocebo response was 45.36% (95%CI:40.47%–50.29%). The placebo and nocebo responses were greater in trials with longer duration, evaluating pharmacological interventions and idiopathic RLS, and in industry funded and unpublished studies. The placebo response was considerable smaller in objective as compared to subjective outcomes. In addition, the nocebo response increases proportionally with the placebo response, and has the same predictors. Conclusions: The magnitude of the placebo response in RLS is above the threshold of minimal clinical important difference, and the frequency of adverse events is also considerable. These results are relevant to inform the design and interpretation of future clinical trials.